Nile Therapeutics (NLTX) Misses Q3 EPS by 3c
More News related to NLTX
- Nile Therapeutics to Present at BIO CEO and Investor Conference
- Nile Therapeutics (NLTX) Misses Q3 EPS by 3c
- Nile Therapeutics (NLTX) Announces Private Placement, Raising $3.4M
- Ladenburg Thalmann Downgrades Nile Therapeutics (NLTX) to Neutral
- Nile Therapeutics (NLTX) Misses Q2 EPS by 4c
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
Nile Therapeutics, Inc. (NASDAQ: NLTX) reports a Q3 loss of $0.08, 3 cents worse than estimates.
Net cash used in operating activities in the third quarter of 2009 was $1.0 million. As of September 30, 2009, Nile had cash and cash equivalents of approximately $4.2 million compared to approximately $5.5 million as of December 31, 2008.
[SM]
Related Categories
EarningsStocks Mentioned
+0.17Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
